EVALUATION OF EFFICACY, SAFETY AND PATIENT' SATISFACTION OF THERAPEUTIC SWITCH FROM OFF-LABEL SWALLOWED TOPICAL CORTICOSTEROIDS TO BUDESONIDE ORODISPERSIBLE TABLETS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Gaia Pellegatta

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

A prospective study of 29 eosinophilic esophagitis patients switching from off-label swallowed topical steroids to budesonide orodispersible tablets found maintained or improved histologic remission with significantly higher patient satisfaction.

KEY POINTS

- Among 8 patients histologically active on off-label swallowed topical steroids, 7 (87.5%) achieved deep remission after switching to budesonide orodispersible tablets, while 10 of 11 (90.91%) patients already in remission maintained it.
- Symptom severity improved significantly after the switch as measured by DSS score (5.14±2.77 to 2.3±2.05, p=0.012), but not by DSQ score (p=0.60).
- Patient satisfaction with treatment increased significantly after switching to budesonide orodispersible tablets (38.21±11.61 to 55.91±14.30, p=0.003).
- Three patients (10.3%) developed oral or esophageal candida infection after the switch, two of whom had previously experienced candida under off-label swallowed topical steroids.
- This study is relevant for gastroenterologists managing PPI non-responsive eosinophilic esophagitis patients currently using off-label topical steroid formulations.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e21229be-743c-11ee-a897-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.